Epithelioid sarcoma is a malignant soft tissue tumour of unknown histogenetic origin that in the past has often been confused with other non-malignant and malignant lesions. First described as a tumour entity by Enzinger (1970) , the morphological and ultrastructural characteristics have meanwhile been well documented. Little progress, however, has been achieved in epithelioid sarcoma therapy. Since several strategies of conventional chemotherapy and irradiation proved to be ineffective (Prat et al., 1978; Chase and Enzinger, 1985) the prognosis still remains poor when the tumour is beyond the reach of curative surgery or has already metastasised.
One important reason limiting the development of new anti-cancerous strategies in epithelioid sarcoma therapy has been the absence of an epithelioid sarcoma cell line, for a long time preventing controlled investigations in vitro. To date, only three human epithelioid sarcoma cell lines have successfully been established (Reeves et al., 1987; Gerharz et al., 1990; Sonobe et al., 1993) and data on drug sensitivity are still scarce. Recently, we succeeded in establishing the human epithelioid sarcoma cell line, GRU-1, (Gerharz et al., 1990) , which is characterised by a mixed mesenchymal-epithelialneural phenotype with co-expression of vimentin, cytokeratin and neurofilament proteins. Subsequently, three clonal subpopulations (GRU-1A, GRU-IB, and GRU-1C), differing in both morphological and biological characteristics have been isolated from GRU-1 (Engers et al., 1994) reflecting tumour heterogeneity, which is commonly accepted as an important cause of drug resistance in tumour therapy.
Retinoic acid (RA) has been shown to exhibit pleiotropic effects on malignant and non-malignant cells. Thus, RA induced terminal differentiation in different tumour cell lines and also affected tumour cell invasion, metastasis and proliferation (Gabbert et al., 1988; McGarvey et al., 1990; Gerharz et al., 1993) . These effects are thought to be mediated by two different classes of nuclear retinoid receptors: retinoic acid receptors (RARs) and retinoid X receptors (RXRs) (Chambon, 1993; Mangelsdorf, 1994) .
TNF-a is known to be a pleiotropic cytokine, capable of eliciting a wide variety of biological responses, which are mediated by two different receptors, TNF-R1 and TNF-R2 of 55 kDa and 75 kDa respectively (Tartaglia and Goeddel, 1992; Sidhu and Bollon, 1993) . Among these biological effects, cytotoxic and cytostatic effects on diverse malignant cell lines in vitro (Sugarman et al., 1985; Rutka et al., 1988; Pusztai et al., 1993; Beyaert and Fiers, 1994 ) suggested a possible clinical use for TNF-oa either alone or in combination with other compounds. Recent in vivo studies on several tumours revealed encouraging results when TNF-cx was combined with other cytokines or with conventional chemotherapy (Lejeune et al., 1994a,b) . Little, however, is known about a combined application of TNF-cx and RA.
The present study, therefore, was undertaken to investigate the effects of RA and TNF-a on the tumour cell proliferation of three different clonal subpopulations derived from the human epithelioid sarcoma cell line GRU-1. Furthermore, we tried to correlate the effects of RA and TNF-a with the expression pattern of their receptors.
Materials and methods
Isolation of clonal subpopulations, cell culture and compounds The clonal cell lines GRU-1A, GRU-1B and GRU-1C used in this study were isolated from the epithelioid sarcoma cell line GRU-1 as described previously (Engers et al., 1994 with various concentrations of [125I]TNF-cx (2-20 ng ml-') in a total volume of 0.3 ml of PBS (Gibco) containing 2% fetal calf serum and 0.02% sodium azide. In order to determine non-specific binding, radiolabelled TNF-a was mixed with a 200-fold excess of the unlabelled homologue before the addition of tumour cells. After incubation cells were washed three times, transferred into counting vials and counted by means of a gamma-counter (LKB-Beckmann, Germany). The number of TNF receptors per cell and the dissociation constant (Kd) were determined by Scatchard plot analysis.
Determination of TNF mRNA and TNF receptor mRNA For Northern blot analysis aliquots of the epithelioid sarcoma cell lines were kept at -70°C until RNA preparation. Total cellular RNA was isolated by the guanidine-thiocyanate method as described by Chomczynski and Sacchi (1987) . The RNA concentration was determined by photometry at 260 nm. The quality of total cellular RNA was verified in an ethidium bromide-stained agarose gel. Northern blot analysis was carried out with 25 Mg of RNA of each sample under denaturing conditions with 1% formaldehyde-agarose gel. Before RNA transfer to nylon membranes the gel was stained with ethidium bromide and the equality of RNA amounts loaded in each lane was verified under UV light and photographed. In a second control step the complete RNA transfer from the gel to the nylon membrane was again verified under UV light. Afterwards, the RNA was hybridised with specific DNA probes. The DNA was labelled by incorporation of [32P]dCTP using an oligolabelling kit (Pharmacia, Germany). The probes were obtained from the purified inserts of the following plasmids, which were kindly provided by Dr K Pfizenmaier, Germany: TNF-RI (pAD-CMV1), insert:Sall/Xba; TNF-R2 (pBluescript SK), insert: EcoRI; TNF-R2 (PCDM8), insert: XhoI/ScaI; TNF-a (pBR322), insert: EcoRI. Hybridisations were performed in 5 x SSC (1 x SSC=0.15 M sodium chloride/0.015 M sodium citrate)/50% formamide/I x Denhardt's solution (1 x Denhardt's solution= 0.02% bovine serum albumin/0.02% Ficoll/0.02% polyvinylpyrrolidone) and 100 Mg denatured salmon sperm DNA per ml at 42°C for 18 h. Filters were washed in 2 x SSC/0.1% sodium dodecyl sulphate for 30 min at room temperature and in 0.1 x SSX/0. 1% sodium dodecyl sulphate for 60 min at 60°C. Fluorography was carried out by exposure of Kodak X-Omat films for 10 days to dried filters at -70°C, in conjunction with intensifying screens. All experiments were done twice and the results could be reproduced.
Determination of RA recptors RAR-a, RAR-f, and RAR-y expression were determined by means of reverse transcriptase-PCR (RT-PCR). Total cellular RNA was prepared according to Stallcup and Washington (1983) . PCR was run using RAR-specific primer sets as described by Ferrari et al. (1994) for 30 cycles (denaturation at 94°C for 1 min, primer annealing at 55°C for 1 min, extension at 72°C for 1 min). PCR products were transferred to a nylon membrane by Southern blotting. RARspecific oligonucleotides (RAR-a: 5'-CCT TGC TTT GTC TGT CAG G-3'; RAR-,B: 5'-TGC ATC CTC CAG GAG -AAA GCT-3'; RAR-y: 5'-GGG TCA GCT CTT GT-G AAG GC-3') were radiolabelled at the 5'-end with [y-32P]ATP using a commercially available T4 polynucleotide kinase (Pharmacia). Southern blots were prehybridised at 50°C for at least 3 h in 5 x SSPE, 2 x Denhardt's solution, tRNA and 0.1% sodium dodecyl sulphate (SDS). After adding the radiolabelled oligonucleotide probes blots were incubated at 50°C for 18-22 h, followed by two washes in 2 x SSPE, 0.05% SDS, 5 x SSPE, and 0.1% SDS. Subsequently, autoradiography was performed. The calculated length of PCR products were 226 bp (RAR-a); 388 bp (RAR-/); 351 bp (RAR-y) respectively.
Determination of TNF production For quantitative determination of TNF-a production by GRU-1A, GRU-1B and GRU-IC triplicate confluent tumour cell cultures were exposed to serum-free culture medium supplemented with 5 ,ug insulin ml-', 5 Mug of transferrin and 5 pg of sodium selenite (Sigma). After 3 days, conditioned media were collected and concentrated by ultrafiltration using Centriprep-10 and Centricon-10 centrifugal microconcentrator devices (Amicon, Germany) according to the manufacturer's manual. The amount of TNF-a was determined on WEHI164c113S cells in an 18 h assay in the presence of 1 jug ml-' actinomycin D as described by Vanhaesebroek et al, (1992) sebroeck et al., 1991, 1992) were used in parallel as negative and positive controls respectively. The obtained results were calibrated with respect to both mouse and human TNF-c standards using a Curve Fit program.
Results
In vitro morphology Tumour cells of GRU-1A, GRU-IB, and GRU-IC exhibited a mainly epithelial-like, polygonal appearance and grew strictly anchorage-dependent as monolayers without evidence of cells piling up. Immunohistochemically, major differences could be detected in the quantitative expression of cytokeratin 18, vimentin and neurofilament proteins (Figure 1 and Table I ). In order to investigate the effects of RA on tumour cell differentiation as defined by the distribution of these intermediate filaments, tumour cells were incubated for 5 days in medium supplemented with different concentrations of RA. As summarised in Table I Effects of RA and/or TNF-x on tumour cell proliferation (Figure 2 ) Proliferation analysis by MTT assay revealed growthinhibitory effects for both RA and TNF -a in subpopulation GRU-1A. Thus, exposure to RA-containing medium resulted in a statistically significant dose-dependent growth inhibition to 82%+5% (0.1 4uM RA, P=0.03) or 71%+5.5% (1 jiM RA, P= 0.01) of the control (= 100%) after an incubation for 5 days in vitro. TNF-a proved to be even more effective than RA, inhibiting tumour cell proliferation dose dependently to 72%+6% (TNF-a 1 ng ml-', P=0.02), 57%+11% (TNF-a 10 ng ml-', P=0.02) and to 49%+4% (TNF-a 100 ng ml-', P = 0.002) of the control (= 100%) after exposure for 5 days. The effects of each singly applied compound could significantly be increased by combined exposure to both compounds. A maximal growth-inhibitory effect was achieved by the combination of RA (1 ,gM) and TNF-a (100 ng ml-'), resulting in an inhibition of tumour cell proliferation to 40% +4% of the control (P= 0.001), which was significantly more effective than the single application of RA (P = 0.006) and TNF-cx TNF-a receptor binding assay (Figure 2) Scatchard analysis revealed the highest number of TNF receptors in the GRU-1A cell line (1999 receptors per cell), while GRU-1B and GRU-1C exhibited 1063 receptors per cell and 1024 receptors per cell respectively. Furthermore, binding affinity could be shown to be essentially higher in GRU-1A (Kd=3.9x 10-', r2=0.98) than in GRU-1B (Kd=7.6x 10-'1, r2=0.98) and in GRU-1C (Kd= 8.5 x 10-10, r2=0.91).
Expression of TNF-RJ and TNF-R2
By Northern blot analysis all cell lines expressed TNF-R1 mRNA, whereas TNF-R2 mRNA was not detected at all (Figure 3a ). In accordance with the results obtained by Scatchard analysis the strongest signal for TNF-R1 mRNA was found in GRU-lA, whereas GRU-lB and GRU-lC expressed TNF-R1 mRNA to a significantly lower extent, not differing between these two cell lines. Since co-incubation of GRU-IA cells in TNF-a and RA resulted in a significantly stronger antiproliferative effect when compared with each single compound, the effect of RA on the expression of TNFRl mRNA was investigated, showing that an incubation period of 5 days in 1 pM RA did not significantly influence TNF-Rl mRNA expression.
TNF production Conditioned media from GRU-lA, GRU-IB and GRU-1C did not contain cytotoxic activity towards WEHI164c113S cells, whereas conditioned media of L929sATmTNFWTC3 and L929M1.lhigh prod cells used as positive controls exhibited marked cytotoxic activities in the range of 3.6 x 104-4.4 x 106 IU ml-'. Furthermore, no TNF-a mRNA could be detected in GRU-1A, GRU-IB, or GRU-IC as evidenced by Northern blot analysis (data not shown).
GRU-1A (4) (Prat et al., 1978; Chase and Enzinger, 1985 (Chase and Enzinger, 1985) . The present study clearly shows that both RA and TNF-a are able to exhibit significant antiproliferative effects on epithelioid sarcoma in vitro, although the results differ markedly between the three clonal subpopulations. Thus, RA dose-dependently inhibited tumour cell proliferation of GRU-1A and GRU-1B after an incubation period of 5 days, whereas no effect was seen in GRU-1C. The effects of RA are known to be mediated through two classes of nuclear retinoid receptors: retinoic acid receptors (RARs) which bind all-trans retinoic acid (RA), the compound used in our study; and retinoid X receptors (RXRs), which bind 9-cis retinoic acid with high affinity (Chambon, 1993; Mangelsdorf, 1994) . Both classes of receptors have been found to consist of at least three different isoforms each (ax, fi, y), the functional impact of these isoforms still far from being elucidated (Chambon, 1993; Mangelsdorf, 1994) . In our tumour model RAR-a was expressed only in GRU-1B, whereas RAR-fl was not detected in any cell line. RAR-y was found in GRU-1A and GRU-1C. No direct correlation, however, between the RA-induced growth inhibition, observed in GRU-1A and GRU-1B, and the expression pattern of RARs became evident. Similar results have been reported by van der Leede et al. (1993) for other tumour models. Interestingly in this context, a marked reduction of plating efficiency by RA was found exclusively in GRU-1B, the only cell line expressing RAR-a, while GRU-IA and GRU-1C proved to be resistant. Nevertheless, it remains to be determined whether the association between RAR-a expression and reduction of plating efficiency is causative rather than coincidental.
In other tumour models growth-inhibitory effects of RA have previously been. shown to be coupled with a simultaneous induction of differentiation (Mummery et al., 1984; Gabbert et al., 1988; Joyce and Steer, 1992) . In spite of significant growth-inhibitory effects, however, RA failed to exhibit any differentiation-inductive effects in GRU-1A and GRU-1B. Thus, immunohistochemical analysis revealed no change in the distribution pattern of cytokeratin 18, vimentin or neurofilament proteins, indicative for epithelial, mesenchymal and neural differentiation respectively. The uncoupling of growth inhibition and differentiation induction observed in GRU-1A and GRU-1B after exposure to RA could result from the complexity of RA signal transduction pathways. Thus, receptor heterodimerisation, which has recently been reported to occur between RARs and RXRs (Marks et al., 1992; Nagpal et al., 1993) , may result in multiple mutually distinct receptors, each of which presumably activates specific target genes in the regulation of proliferation and differentiation.
TNF-a exhibited a highly significant antiproliferative effect in GRU-1A, whereas GRU-1B and GRU-1C proved to be TNF-resistant. TNF-a is known to exhibit a multitude of different effects upon binding to two distinct high-affinity receptors, TNF-R1 and TNF-R2 (Tartaglia and Goeddel, 1992; Sidhu and Bollon, 1993) , the specific functional impact of each receptor type on growth regulation and cytotoxicity still being under discussion (Heller et al., 1992; Tartaglia et al., 1993; Grell et al., 1993; Higuchi and Aggarwal, 1994) . In our tumour model, however, the antiproliferative effect of TNF-a was exclusively mediated by TNF-R1 since no TNF-R2 mRNA was detectable. Furthermore, a positive correlation between TNF-ax-induced growth inhibition and both the number of TNF-R1 and receptor affinity became evident. In addition, it was excluded on both the mRNA and protein level that TNF resistance in GRU-1B and GRU-1C was due to endogenous TNF-a production, as has been reported from other tumour models (Vanhaesebroeck et al., 1992) , since all subpopulations of GRU-1 proved to be TNF negative. Finally, it was shown that the combined exposure to RA 496 $9
Growth inhibition in epithelioid sarcoma R Engers et al ! 497 and TNF-oa resulted in an additive rather than a synergistic antiproliferative effect in GRU-lA. In accordance with this observation, RA did not significantly alter TNF-R1 mRNA expression in the same cell line, suggesting that the antiproliferative effects of both compounds might be mediated by independent signal transduction pathways.
In conclusion, RA and TNF-cx have been shown to exhibit significant and in part additive growth-inhibitory effects in human epithelioid sarcoma, the response, however, markedly differing between the three clonal subpopulations of our tumor model. The antiproliferative effects of TNF-a were mediated by TNF-RI and correlated with both the number of TNF-RI and receptor affinity. Therefore, the clonal subpopulations GRU-1A, GRU-1B and GRU-1C provide an excellent human in vitro model to investigate TNF resistance and TNF signalling pathways as well as the susceptibility of epithelioid sarcoma for new therapeutic strategies, taking into account tumour heterogeneity.
